Trial Profile

A Randomized Phase 2 Study of Gataparsen in Combination With Docetaxel Versus Docetaxel Alone in Hormone Refractory Prostate Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gataparsen (Primary) ; Docetaxel; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004130).
12 May 2012 Actual end date (2 Apr 2012) added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com